Salesforce shares are underperforming in 2025, leading investors to consider the potential for 2026.
1 extracted signal · 1 resolved · 0 still active
Parkev Tatevosian, CFA25 Sept 2025, 18:45 UTC
AI-generated source summary
The analysis predicts a target price for Salesforce (CRM) stock to be between $300 and $320 within the next 12 months, based on forward price-to-earnings ratio of 22 and an EPS of $14.50, and the CRM will not reach the predicted price if the fail bound gets $240. It highlights that Salesforce is currently trading at a relatively low forward P/E ratio, comparable to January 2023 levels. The analysis assumes the company will deliver on estimated earnings per share. The analysis also notes that the market is currently unimpressed with Salesforce's AI strategy. The current price mentioned is $245.53.
AI-generated summary based on the source content.
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
Signals in this source
More Prediction Case Files from Parkev Tatevosian, CFA
Coca-Cola Stock: Buy, Hold, or Sell? | KO Stock Analysis
SoFi Stock Analysis: Buy the Dip?
Should You Buy Micron Stock Instead of Nvidia Stock? | MU Stock vs. NVDA Stock
Should You Buy the Dip in Meta Stock? | META Stock Analysis and Live Earnings Review
Should Passive Income Investors Buy Colgate Palmolive Stock?
Procter & Gamble Stock: Buy, Hold, or Sell? | PG Stock Analysis
Parkev Tatevosian, CFA
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.